01:17:13 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-28 Bokslutskommuniké 2024
2024-11-15 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-27 X-dag ordinarie utdelning INIT 0.00 SEK
2024-05-24 Årsstämma 2024
2024-05-10 Kvartalsrapport 2024-Q1
2024-02-23 Bokslutskommuniké 2023
2023-11-10 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-29 X-dag ordinarie utdelning INIT 0.00 SEK
2023-05-26 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-11-04 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-23 X-dag ordinarie utdelning INIT 0.00 SEK
2022-05-20 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-18 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-31 X-dag ordinarie utdelning INIT 0.00 SEK
2021-05-28 Årsstämma 2021
2021-05-25 Kvartalsrapport 2021-Q1
2021-05-11 Extra Bolagsstämma 2021
2021-02-19 Bokslutskommuniké 2020
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-25 X-dag ordinarie utdelning INIT 0.00 SEK
2020-05-22 Årsstämma 2020
2020-05-22 Kvartalsrapport 2020-Q1
2020-02-21 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-24 X-dag ordinarie utdelning INIT 0.00 SEK
2019-05-23 Kvartalsrapport 2019-Q1
2019-05-23 Årsstämma 2019
2019-02-22 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-28 X-dag ordinarie utdelning INIT 0.00 SEK
2018-05-25 Årsstämma 2018
2018-05-25 Kvartalsrapport 2018-Q1
2018-03-01 Extra Bolagsstämma 2017
2018-02-21 Bokslutskommuniké 2017
2017-11-24 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-26 Kvartalsrapport 2017-Q1
2017-05-17 X-dag ordinarie utdelning INIT 0.00 SEK
2017-05-16 Årsstämma 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Initiator Pharma är verksamma inom bioteknik. Idag innehas störst affärsinriktning mot utveckling av läkemedelskandidater som används vid behandling av erektil dysfunktion hos män. Bolaget har för tillfället läkemedel under testning i klinisk fas för patienter som inte svarar på PDE5i läkemedel. Initiator Pharma kom till via en spin-off från Saniona och har idag sitt huvudkontor i Åbyhøj.
2022-07-05 08:30:00

The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808,(“Initiator” or the “Company”) has today resolved to carry out a directed share issue to a financial advisor in connection with the recently completed rights issue.

Today the Company’s Board of Directors have decided to increase the Company’s share capital by a total of nominally DKK 34,999.965 divided into 333,333 shares (the “New Shares”) of nominally DKK 0.105 as a result of a directed share issue to one of the financial advisors in connection with the Company’s recently completed rights issue. The New Shares have been issued without pre-emption rights for the existing shareholders subject to the board authorisation in article 4b in the Company’s articles of association.

The capital increase in connection with the subscription of New Shares by the private investor amounts to nominally DKK 34,999.965 corresponding to 333,333 shares of nominally DKK 0.105. The New Shares have been subscribed for by cash contribution at a price of SEK 7.5 per share (corresponding to DKK 5.1825 per share) and the deadline for payment of the shares is 7 days from today. As a result, the Company’s expects gross proceeds of approximately DKK 1.7 million. In the view of the Board of Directors, the price per share of SEK 7.5 reflects the current market value.

The New Shares will upon issuance be subject to the same rights as existing shares under the Company’s articles of association and is expected to be admitted to trading on Nasdaq First North Growth Market under the existing ISIN code DK0060775872 once the capital increase has been registered with the Danish Business Authority.

After the capital increase, the total nominal value of the Company’s share capital will amount to nominally DKK 4,924,338.4 divided into 46,898,461 shares of nominally DKK 0.105 each corresponding to 46,898,461 votes.

The Company will send out a new company announcement when the capital increase has been registered with the Danish Business Authority.